

Ministry of Health - MS
National Health Surveillance Agency - ANVISA

RESOLUTION OF THE COLLEGIATE BOARD - RDC N° 385, OF MAY 12, 2020

(Published in DOU n° 90, of May 13, 2020)

Changes the Board Resolution
Collegiate - RDC n° 346, of 12
March 2020.

The **Collegiate Directorate of the National Health Surveillance Agency**, using the attribution that art. 15, III and IV, allied to art. 7, III and IV of Law 9.782, of January 26, 1999, and to art. 53, V, §§ 1 and 3 of the Internal Regulation approved by Collegiate Board Resolution - RDC No. 255, of December 10, 2018, resolves adopt the following Collegiate Board Resolution, as resolved at a meeting held on May 12, 2020, and I, Deputy Chief Executive Officer, determine your Publication.

Art. 1 Repeal art. 7 of the Collegiate Board Resolution - RDC n° 346, of March 12, 2020, which defines the extraordinary criteria and procedures and for the certification of good manufacturing practices for the purposes of registration and post-registration changes to active pharmaceutical ingredient, medication and products for health due to the international public health emergency of the New Coronavirus.

Art. 2 This Resolution enters into force on the date of its publication.

ANTONIO BARRA TORRES

This text does not replace the one (s) published in the Federal Official Gazette.